Last reviewed · How we verify
Desitin Arzneimittel GmbH — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| pramipexole or ropinirole | pramipexole or ropinirole | phase 3 | Dopamine agonist | Dopamine receptor | Neurology |
Therapeutic area mix
- Neurology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Beijing Bozhiyin T&S Co., Ltd. · 1 shared drug class
- Beth Israel Deaconess Medical Center · 1 shared drug class
- Britannia Pharmaceuticals Ltd. · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Intec Pharma Ltd. · 1 shared drug class
- Leiden University Medical Center · 1 shared drug class
- Ludwig-Maximilians - University of Munich · 1 shared drug class
- Axxonis Pharma AG · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Desitin Arzneimittel GmbH:
- Desitin Arzneimittel GmbH pipeline updates — RSS
- Desitin Arzneimittel GmbH pipeline updates — Atom
- Desitin Arzneimittel GmbH pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Desitin Arzneimittel GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/desitin-arzneimittel-gmbh. Accessed 2026-05-16.